Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) has issued an update.
On September 12, 2025, Shuttle Pharmaceuticals Holdings, Inc. appointed Sachin Pathigoda and Angel Liriano as directors, with further appointments to key committee roles on September 15, 2025. These strategic appointments, including George Scorsis as Chairman of the Audit Committee, aim to strengthen the company’s governance structure, potentially enhancing its operational oversight and stakeholder confidence.
Spark’s Take on SHPH Stock
According to Spark, TipRanks’ AI Analyst, SHPH is a Underperform.
Shuttle Pharmaceuticals Holdings, Inc. faces significant financial challenges with no revenue and ongoing cash burn. Technical indicators show bearish trends, and valuation metrics highlight the company’s unprofitability. While recent corporate activities offer potential strategic benefits, they also add financial strain and governance complexities, leading to an overall low stock score.
To see Spark’s full report on SHPH stock, click here.
More about Shuttle Pharmaceuticals Holdings, Inc.
Average Trading Volume: 108,366
Technical Sentiment Signal: Sell
Current Market Cap: $4.67M
Learn more about SHPH stock on TipRanks’ Stock Analysis page.